The Molecular Oncology Training Program is a unique project at Washington University School of Medicine, designed to train graduate students and postgraduate scientists in interdisciplinary research relevant to cancer biology. From 2006 to 2010, this program supported 1 predoctoral student and 4 postdoctoral scientists each year through NIH funds, and an additional 6 predoctoral students through Siteman Cancer Center funds. The program provides 2 yrs of support for trainees to conduct laboratory research in 1 of 21 laboratories of highly experienced and productive faculty mentors. Furthermore the program includes a required spring didactic course in cancer biology, with emphasis on adult oncology or pediatric oncology in alternate years. Trainees participate in a cancer-related journal club in the fall of each year. Moreover, trainees also participate in a Clinical/Translatioal Mentoring Program each fall, occupying 1/2 day each month in one of eight areas of oncology: Medical, Radiation, Gynecologic, Pathologic, Radiologic, or Surgical Oncology, Stem Cell Transplantation, or Genomics/Proteomics/Nanotechnology. The program makes use of extensive mechanisms of evaluation by trainees, program steering committee, laboratory mentors, and internal and external advisors in order to address important areas for change and improvement.
The Molecular Oncology Training Program supports a 2 yr period of training for graduate students working towards PhD and postdoctoral fellows with PhD who desire a broad education in interdisciplinary cancer research. Trainees participate each fall in a weekly cancer-related journal club, as well a Clinical/Translational Mentoring Program one half day per month in Medical, Radiation, Gynecologic, Pathologic, Radiologic, or Surgical Oncology, Stem Cell Transplantation, or Genomics/Proteomics/Nanotechnology. Each spring semester, trainees participate in a didactic course emphasizing adult or pediatric oncology in alternate years. Trainees also participate in a wide range of seminar programs supported by the Siteman Cancer Center, and basic laboratory cancer research with highly skilled and productive faculty mentors. The program has been jointly supported by the NCI training grant support mechanism with approximately matching funds from Siteman Cancer Center.
|Celik, Hamza; Koh, Won Kyun; Kramer, Ashley C et al. (2018) JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer Cell 34:741-756.e8|
|Murali, Bhavna; Ren, Qihao; Luo, Xianmin et al. (2018) Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res 78:5618-5630|
|Jeong, Mira; Park, Hyun Jung; Celik, Hamza et al. (2018) Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 23:1-10|
|Cotto, Kelsy C; Wagner, Alex H; Feng, Yang-Yang et al. (2018) DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res 46:D1068-D1073|
|Wagner, Alex H; Devarakonda, Siddhartha; Skidmore, Zachary L et al. (2018) Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun 9:3787|
|Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521|
|Ostrander, Elizabeth L; Koh, Won Kyun; Mallaney, Cates et al. (2018) The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. Exp Hematol 57:14-20|
|Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060|
|Halstead, Angela M; Kapadia, Chiraag D; Bolzenius, Jennifer et al. (2017) Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife 6:|
|Kramer, A C; Kothari, A; Wilson, W C et al. (2017) Dnmt3a regulates T-cell development and suppresses T-ALL transformation. Leukemia 31:2479-2490|
Showing the most recent 10 out of 115 publications